Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Jazz pharmaceuticals plc save search
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -0.25%
H: 1.25%
C: 0.99%
pharmaceuticals meeting
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav®
Published: 2023-10-23 (Crawled : 12:00) - biospace.com/
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -1.39%
H: 0.09%
C: -2.36%
xywav treatment pharmaceuticals
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Published: 2023-09-22 (Crawled : 15:00) - biospace.com/
LGND | $80.01 0.3% 0.3% 160K
|
Health Technology
|
| O: -0.07%
H: 1.1%
C: -0.34%
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -0.02%
H: 0.89%
C: -0.72%
enrylaze approval treatment pharmaceuticals leukemia
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Published: 2023-09-21 (Crawled : 22:00) - prnewswire.com
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -0.02%
H: 0.89%
C: -0.72%
enrylaze approval treatment pharmaceuticals leukemia
Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: 0.06%
H: 2.72%
C: 2.14%
jzp458 chmp positive treatment pharmaceuticals leukemia
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
Published: 2023-05-31 (Crawled : 16:00) - biospace.com/
INAB | $0.9851 -3.42% -3.54% 180K
|
|
| O: 0.35%
H: 6.57%
C: 5.19%
VCYT | $18.92 -2.32% -2.38% 680K
|
Health Technology
|
| O: -0.43%
H: 3.05%
C: 1.21%
ONCY | $1.07 0.94% 0.93% 260K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.81%
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -0.09%
H: 2.57%
C: 1.13%
GERN | $3.6 4.35% 4.17% 6.4M
|
Health Technology
|
| O: 0.6%
H: 2.1%
C: -2.1%
asco cancer meeting set
Sleep Disorders Treatment Global Market Report 2023: Growing Demand for Home Sleep Tests Presents Opportunities
Published: 2023-03-31 (Crawled : 19:00) - prnewswire.com
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.966 -2.18% 630
|
Health Technology
| Email alert
Add to watchlist
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
| Email alert
Add to watchlist
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
| Email alert
Add to watchlist
report treatment global growing home market
Dravet syndrome treatment market size to increase by USD 575.14 million; North America to contribute 38% of market growth - Technavio
Published: 2023-01-17 (Crawled : 19:00) - prnewswire.com
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: -0.17%
H: 0.25%
C: -2.96%
TMO | $554.55 -0.6% 0.0% 1M
|
Health Technology
|
| O: 0.56%
H: 0.97%
C: -1.87%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: -0.46%
H: 0.2%
C: -1.92%
XENE | $41.52 0.51% 0.51% 410K
|
Health Technology
|
| O: -0.17%
H: 1.88%
C: -0.58%
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -0.46%
H: 1.9%
C: -0.12%
america treatment growth market dravet syndrome
Extensive Stage Small Cell Lung Cancer Global Market Report 2022: Need of Potential Treatments to Improve Quality of Life Drives Sector
Published: 2022-12-22 (Crawled : 17:00) - prnewswire.com
AZNCF | $135.94 -4.19% 770
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -0.06%
H: 1.27%
C: 0.93%
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: -0.04%
H: 0.32%
C: 0.31%
lung global report life potential cancer market
Spasticity Treatment Market - 41% of Growth to Originate from North America| Evolving Opportunities with Allergan Plc & Alembic Pharmaceuticals Ltd. | Technavio
Published: 2022-04-23 (Crawled : 04:20) - prnewswire.com
ENDP 6 d | $0.2926 -9.6%
|
Health Technology
| Email alert
Add to watchlist
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
| Email alert
Add to watchlist
MDT | $79.25 -1.22% 0.0% 7.1M
|
Health Technology
| Email alert
Add to watchlist
treatment growth market
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder
Published: 2021-12-30 (Crawled : 14:00) - biospace.com/
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: 0.09%
H: 0.74%
C: -2.58%
jzp150 treatment phase 2 als order trial enroll
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor
Published: 2021-12-15 (Crawled : 13:30) - biospace.com/
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -0.93%
H: 1.39%
C: 0.5%
jzp385 treatment phase 2 als phase 2b trial enroll
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -1.06%
H: 0.0%
C: 0.0%
zepzelca treatment trial lung cancer cancer phase 3
Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca (lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a Decade
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -3.5%
H: 0.0%
C: 0.0%
treatment lung cancer cancer
FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment
Published: 2021-08-12 (Crawled : 21:00) - fda.gov
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -0.14%
H: 1.0%
C: -2.26%
treatment fda granted grant
GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex
Published: 2021-08-10 (Crawled : 09:00) - prnewswire.com
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -0.32%
H: 0.12%
C: -3.88%
treatment sclerosis approval
Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Published: 2021-07-01 (Crawled : 01:00) - prnewswire.com
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: 1.71%
H: 1.13%
C: 0.28%
treatment fda fda approval leukemia approval
Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
Published: 2021-03-30 (Crawled : 23:00) - prnewswire.com
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: 0.37%
H: 0.84%
C: -1.63%
treatment fda myeloid leukemia fda approval leukemia approval acute myeloid leukemia
Global Acute Lymphoblastic Leukemia Treatment Market Research Report (2020 to 2025) - by Types of Cell, Therapy and Region
Published: 2021-03-24 (Crawled : 17:00) - prnewswire.com
TAK | $13.23 0.38% 0.0% 2.3M
|
Health Technology
|
| O: -0.36%
H: 0.36%
C: -0.21%
GSK | $39.95 -1.36% 0.0% 2.4M
|
Health Technology
|
| O: -0.86%
H: 1.01%
C: 0.53%
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 0.95%
H: 0.91%
C: -9.38%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -0.25%
H: 0.39%
C: 0.27%
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: 0.54%
H: 1.24%
C: -0.9%
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: -0.22%
H: 1.09%
C: -0.02%
GMAB | $29.42 -0.31% -0.31% 340K
|
Health Technology
|
| O: -0.76%
H: 0.0%
C: -2.59%
TECH | $64.01 -2.31% -2.36% 1.6M
|
Health Technology
|
| O: 0.32%
H: 1.09%
C: -2.18%
treatment therapy leukemia research
Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Published: 2020-12-21 (Crawled : 20:11) - biospace.com/
JAZZ | $108.92 -1.79% -1.83% 540K
|
Health Technology
|
| O: -1.63%
H: 2.32%
C: 1.34%
license leukemia submission treatment
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.